Therefore, we used an inducible TERT-KD construct, allowing for treatment to commence after tumor formation and growth, replicating the therapeutic scenario in a clinical setting without the confounding off-target effects of small molecule inhibitors. This evidence concerns the gene TERT and neoplasm.